These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 20088518)

  • 1. Design and synthesis of potent Quillaja saponin vaccine adjuvants.
    Adams MM; Damani P; Perl NR; Won A; Hong F; Livingston PO; Ragupathi G; Gin DY
    J Am Chem Soc; 2010 Feb; 132(6):1939-45. PubMed ID: 20088518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semisynthesis of Analogues of the Saponin Immunoadjuvant QS-21.
    Fernández-Tejada A; Walkowicz WE; Tan DS; Gin DY
    Methods Mol Biol; 2017; 1494():45-71. PubMed ID: 27718185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Improved Vaccine Adjuvants Based on the Saponin Natural Product QS-21 through Chemical Synthesis.
    Fernández-Tejada A; Tan DS; Gin DY
    Acc Chem Res; 2016 Sep; 49(9):1741-56. PubMed ID: 27568877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic studies of complex immunostimulants from Quillaja saponaria: synthesis of the potent clinical immunoadjuvant QS-21Aapi.
    Kim YJ; Wang P; Navarro-Villalobos M; Rohde BD; Derryberry J; Gin DY
    J Am Chem Soc; 2006 Sep; 128(36):11906-15. PubMed ID: 16953631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer.
    Ragupathi G; Gardner JR; Livingston PO; Gin DY
    Expert Rev Vaccines; 2011 Apr; 10(4):463-70. PubMed ID: 21506644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and structure verification of the vaccine adjuvant QS-7-Api. Synthetic access to homogeneous Quillaja saponaria immunostimulants.
    Deng K; Adams MM; Gin DY
    J Am Chem Soc; 2008 May; 130(18):5860-1. PubMed ID: 18410100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of the synthetic adjuvant SQS-21 and its constituent isomeric saponins.
    Ragupathi G; Damani P; Deng K; Adams MM; Hang J; George C; Livingston PO; Gin DY
    Vaccine; 2010 Jun; 28(26):4260-7. PubMed ID: 20450868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of the potent immunostimulatory adjuvant QS-21A.
    Wang P; Kim YJ; Navarro-Villalobos M; Rohde BD; Gin DY
    J Am Chem Soc; 2005 Mar; 127(10):3256-7. PubMed ID: 15755124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leaf saponins of Quillaja brasiliensis enhance long-term specific immune responses and promote dose-sparing effect in BVDV experimental vaccines.
    Cibulski S; Rivera-Patron M; Suárez N; Pirez M; Rossi S; Yendo AC; de Costa F; Gosmann G; Fett-Neto A; Roehe PM; Silveira F
    Vaccine; 2018 Jan; 36(1):55-65. PubMed ID: 29174676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and Evaluation of QS-7-Based Vaccine Adjuvants.
    Wang P; Škalamera Đ; Sui X; Zhang P; Michalek SM
    ACS Infect Dis; 2019 Jun; 5(6):974-981. PubMed ID: 30920199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Foamy matters: an update on
    Magedans YV; Yendo AC; Costa F; Gosmann G; Fett-Neto AG
    Future Med Chem; 2019 Jun; 11(12):1485-1499. PubMed ID: 31304830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of QS-21-xylose: establishment of the immunopotentiating activity of synthetic QS-21 adjuvant with a melanoma vaccine.
    Deng K; Adams MM; Damani P; Livingston PO; Ragupathi G; Gin DY
    Angew Chem Int Ed Engl; 2008; 47(34):6395-8. PubMed ID: 18624313
    [No Abstract]   [Full Text] [Related]  

  • 13. QS-21 Adjuvant: Laboratory-Scale Purification Method and Formulation Into Liposomes.
    Brunner L; Barnier-Quer C; Collin N
    Methods Mol Biol; 2017; 1494():73-86. PubMed ID: 27718186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploiting structure-activity relationships of QS-21 in the design and synthesis of streamlined saponin vaccine adjuvants.
    Ghirardello M; Ruiz-de-Angulo A; Sacristan N; Barriales D; Jiménez-Barbero J; Poveda A; Corzana F; Anguita J; Fernández-Tejada A
    Chem Commun (Camb); 2020 Jan; 56(5):719-722. PubMed ID: 31833496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative inactivated poliovirus vaccines adjuvanted with Quillaja brasiliensis or Quil-a saponins are equally effective in inducing specific immune responses.
    de Costa F; Yendo AC; Cibulski SP; Fleck JD; Roehe PM; Spilki FR; Gosmann G; Fett-Neto AG
    PLoS One; 2014; 9(8):e105374. PubMed ID: 25148077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a novel saponin adjuvant derived from Quillaja saponaria on the immune response to recombinant hepatitis B surface antigen.
    So HS; Yoon HS; Choi DY; Kwon YS; Sung JH; Lee TG; Park ES; Cho HS; Lee BM; Cho JM; Ryu WS
    Mol Cells; 1997 Apr; 7(2):178-86. PubMed ID: 9163729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Versatile strategy for the divergent synthesis of linear oligosaccharide domain variants of Quillaja saponin vaccine adjuvants.
    Fernández-Tejada A; Tan DS; Gin DY
    Chem Commun (Camb); 2015 Sep; 51(73):13949-13952. PubMed ID: 26243268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in saponin-based adjuvants.
    Sun HX; Xie Y; Ye YP
    Vaccine; 2009 Mar; 27(12):1787-96. PubMed ID: 19208455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.
    Oliveira-Freitas E; Casas CP; Borja-Cabrera GP; Santos FN; Nico D; Souza LO; Tinoco LW; da Silva BP; Palatnik M; Parente JP; Palatnik-de-Sousa CB
    Vaccine; 2006 May; 24(18):3909-20. PubMed ID: 16556475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and Evaluation of a QS-17/18-Based Vaccine Adjuvant.
    Wang P; Škalamera Đ; Sui X; Zhang P; Michalek SM
    J Med Chem; 2019 Feb; 62(3):1669-1676. PubMed ID: 30656932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.